ClearPoint Neuro sees FDA clearance and launch SmartFrame OR in 2024

Sees FDA clearance and launch SmartFrame OR for navigation and first revenue in the operating room; Launch full market release of the ClearPoint PRISM Neuro Laser Therapy System; Launch and deploy ClearPoint 2.2 Software with embedded ClearPoint Maestro and 1.2 Array Software with parallel trajectory tumor planning application to the installed base; Win first purchase orders for GLP ready pre-clinical services; Prototype demonstration of next generation software application for AI predictive modeling to pharma partners; Continue global expansion to achieve 100 ClearPoint sites by 2025; and”We are thrilled with our fourth quarter performance delivering record revenue of $6.8M, reflecting 32% growth, while meaningfully reducing our cash burn and gaining commitments for multiple new ClearPoint installations,” commented Joe Burnett, President and CEO at ClearPoint Neuro.”In 2024, we look forward to several new product introductions reflecting success with the strategic investments we have made to expand our leadership position, including the SmartFrame OR for our entrance into the operating room; the full market release of the PRISM laser therapy system; the integration of ClearPoint Maestro into our navigation software; and the expansion of our pre-clinical biologics and drug delivery services including GLP readiness. These represent four new potential revenue streams that we plan to add to our base business throughout the year.” Management will be available for meetings in San Francisco during the J.P. Morgan Healthcare Conference from January 8-11, 2024.